Matched cohort outcomes
| Mean (SE) | Dronabinol cases (n=33) | Non-dronabinol controls (n=33) | Difference | P value |
| Primary outcome | ||||
| Change in MME | −78.7 (20.2) | −8.6 (17.6) | −70.2 (28.8) | 0.02 |
| Change in MME* | −96.5 (24.5) | 11.2 (28.4) | −107.7 (39.8) | 0.01 |
| Secondary outcomes | ||||
| MME on treatment | 90.0 (17.5) | 121.0 (27.0) | −30.9 (33.2) | 0.36 |
| Pain NRS on treatment | 5.3 (0.3) | 4.3 (0.3) | 0.9 (0.5) | 0.07 |
| Change in pain NRS | −0.4 (0.3) | −0.6 (0.4) | 0.1 (0.5) | 0.78 |
| Change in non-opioid multimodal pain adjuncts | ||||
| Acetaminophen, mg | −468 (466) | −434 (268) | −34 (485) | 0.94 |
| Cyclobenzaprine, mg | −5.5 (3.3) | 0 (1.7) | −5.5 (3.5) | 0.12 |
| Methocarbamol, mg | 7.6 (68) | −136 (111) | 144 (130) | 0.28 |
*Cases using marijuana (n=19) and their matched controls (n=19).
MME, morphine milligram equivalents; NRS, numeric rating score.